Photo from wikipedia
ABSTRACT CD19 immunotherapies based on T cells opened new avenues in the treatment of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, Fc engineered CD19 antibodies may also bear great… Click to show full abstract
ABSTRACT CD19 immunotherapies based on T cells opened new avenues in the treatment of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, Fc engineered CD19 antibodies may also bear great potential. In light of recent preclinical and clinical data, perspectives of such antibodies designed for improved effectiveness in BCP-ALL are presented.
Keywords:
precursor acute;
lymphoblastic leukemia;
cell precursor;
acute lymphoblastic;
pediatric cell
Journal Title: Oncoimmunology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Oncoimmunology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!